Sponsor study identifier
Secondary identifiers
observational
26
1 country
1
Study Start
April 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 7, 2023
Actual (reported)Study Completion
March 7, 2023
Actual (reported)Insulin Resistance is the best predictor of whether the obese adolescent will develop type 2 diabetes. The present studies will focus on determining what might cause fat to accumulate in the subcutaneous fat regions and lead to local inflammation, causing insulin resistance to develop in obese adolescents.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 7, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 16, 2015
Actual (reported)March 20, 2015
Actual (reported)April 2016
Date type not reportedThis date has not been verified as actual or estimated.
March 7, 2023
Actual (reported)March 7, 2023
Actual (reported)Fat Biopsies
1\) To test whether the reduced transcription of key lipogenic/adipogenic genes in abd SAT in obese adolescents with a High VAT/SAT ratio translates functionally into a reduced in vivo TG synthesis and adipocyte proliferation, which in turn will contribute to ectopic fat accumulation and IR.
Baseline
MRI
Baseline
Subjects with a high ratio of visceral to subcutaneous fat consuming high Palmatite oil diet for 12 weeks
Subjects with a low ratio of visceral to subcutaneous fat
Lean control
Subjects with a high ratio of visceral to subcutaneous fat consuming low Palmatite oil diet for 12 weeks
Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Obese adolescents
Yale
New Haven, Connecticut, 06511, United States
Basal plasma samples for measurements of glucose and glycerol enrichment, and glucose, insulin FFAs, leptin, C-peptide, glucagon, adiponectin, cortisol, growth hormone, catecholamines and amino acids, will be collected.
Sonia Caprio, MD
Yale University
26 participants (actual enrollment reported by the registry).
First Submitted
March 16, 2015
First Posted
March 20, 2015
Study Start
April 2016
Date type not reportedThis date has not been verified as actual or estimated.
Mechanisms of Obesity and Its Metabolic Complications in Youth
Contact the study team to confirm eligibility.
Primary Completion
March 7, 2023
Actual (reported)Study Completion
March 7, 2023
Actual (reported)Last Updated
February 26, 2024
Record last verified: 2024-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: